Skye Bioscience (SKYE) Current Leases (2021 - 2026)
Skye Bioscience (SKYE) posted quarterly Current Leases of $60980.0 for Q1 2026, down 67.67% year-over-year from $188645.0 in Q1 2025, and down 67.85% quarter-over-quarter from $189647.0 in Q4 2025.
Skye Bioscience (SKYE) Current Leases (2021 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Current Leases for 6 consecutive years, with $60980.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases fell 67.67% year-over-year to $60980.0; the TTM figure through Mar 2026 stood at $60980.0 (down 67.67% YoY), while the FY2025 annual figure was $189647.0, up 3.96% from the prior year.
- Current Leases eased to $60980.0 in Q1 2026 per SKYE's latest filing, from $189647.0 in the prior quarter.
- Across five years, Current Leases topped out at $201638.0 in Q3 2025 and bottomed at $60980.0 in Q1 2026.
- Historically, Current Leases has averaged $111122.7 across 5 years, with a median of $82932.0 in 2024.
- Annual changes were most pronounced in 2024 — Current Leases jumped 153.24% — and 2026, when it slumped 67.67%.
- Skye Bioscience's Current Leases stood at $78700.0 in 2022, then retreated by 8.47% to $72038.0 in 2023, then jumped by 153.24% to $182428.0 in 2024, then grew by 3.96% to $189647.0 in 2025, then slumped by 67.85% to $60980.0 in 2026.
- Business Quant data shows SKYE's Current Leases at $60980.0 in Q1 2026, $189647.0 in Q4 2025, and $201638.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Skye Bioscience | 10.71 Mn | 10.71 Mn | - | 35,696.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,980.00 |
| Dec 31, 2025 | 189,647.00 |
| Sep 30, 2025 | 201,638.00 |
| Jun 30, 2025 | 195,046.00 |
| Mar 31, 2025 | 188,645.00 |
| Dec 31, 2024 | 182,428.00 |
| Sep 30, 2024 | 82,932.00 |
| Jun 30, 2024 | 79,165.00 |
| Mar 31, 2024 | 75,535.00 |
| Dec 31, 2023 | 72,038.00 |
| Sep 30, 2023 | 68,677.00 |
| Jun 30, 2023 | 65,452.00 |
| Mar 31, 2023 | 81,318.00 |
| Dec 31, 2022 | 78,700.00 |
| Sep 30, 2022 | 92,356.00 |
| Jun 30, 2022 | 88,928.00 |
| Mar 31, 2022 | 85,601.00 |
| Dec 31, 2021 | 82,372.00 |
| Sep 30, 2021 | 63,581.00 |